A randomised, double-blind phase II study evaluating cediranib vs cediranib and saracatinib in patients with relapsed metastatic clear cell renal cancer (COSAK).
Authors
Powles, TBrown, J
Larkin, J
Jones, R
Ralph, C
Hawkins, Robert E
Chowdhury, S
Boleti, E
Bhal, A
Fife, K
Webb, A
Crabb, S
Geldart, T
Hill, R
Dunlop, J
Hall, P
McLaren, D
Ackerman, C
Beltran, L
Nathan, P
Affiliation
The Royal Free NHS Foundation Trust, London, UK Barts Cancer Institute, CRUK Experiment Cancer Medicine CentreIssue Date
2016-01-22
Metadata
Show full item recordAbstract
Preclinical work suggests Src proteins have a role in the development of resistance to vascular endothelial growth factor (VEGF) targeted therapy in metastatic clear cell renal cancer (mRCC). This hypothesis was tested in this trial using the SRC inhibitor saracatinib and the VEGF inhibitor cediranib.Citation
A randomised, double-blind phase II study evaluating cediranib vs cediranib and saracatinib in patients with relapsed metastatic clear cell renal cancer (COSAK). 2016: Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdw014PubMed ID
26802156Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdw014